-+ 0.00%
-+ 0.00%
-+ 0.00%

China NMPA clears Heidelberg Pharma’s HDP-101 combo trial in multiple myeloma

PUBT·08/27/2026 09:15:54
Listen to the news
China NMPA clears Heidelberg Pharma’s HDP-101 combo trial in multiple myeloma
  • China’s NMPA cleared a Phase Ib/II combination trial of Heidelberg Pharma’s HDP-101 in relapsed or refractory multiple myeloma.
  • Huadong Medicine will run the study in China, covering development costs under its regional licensing deal for HDP-101.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.